Orchestrating gut health®
Our mission is to transform the standard of care for patients with gastrointestinal disease
EnteroBiotix is a clinical-stage microbiome therapeutics company advancing EBX-102-02®, an orally delivered, full-spectrum microbiome drug in clinical development for the treatment of irritable bowel syndrome (IBS) and other diseases linked to the gastrointestinal tract and the liver
EBX-102-02®
EBX-102-02® is an investigational, orally administered microbiome-based therapeutic under clinical development.
It is a high-diversity microbial product formulated as an off-white colour, odourless powder and manufactured using EnteroBiotix’s proprietary AMPLA™ drying technology. The formulation is designed to be refrigerator-stable and suitable for scalable manufacture.
EBX-102-02® is protected by granted composition of matter patents.
The product is currently being evaluated in clinical studies in irritable bowel syndrome and other diseases.
Safety and efficacy have not been established. This information is provided for scientific and corporate background purposes only.
IBS a large and global
unmet medical need
IBS is one of the largest unmet medical needs in modern medicine, driven by gut dysfunction, microbiome imbalance, and low-grade immune activation. Current treatments are largely symptomatic and do not address any underlying microbiome dysbiosis. As a result, many patients experience persistent symptoms and limited durable benefit from existing therapies, often cycling through multiple over-the-counter treatments in an attempt to self-manage their condition.
Prevalence
~11% pf patients globally have substantial underdiagnosis and mismanagement of their current treatments
Current standard of care landscape
No curative or disease-modifying therapies; current treatments offer limited relief and are often poorly tolerated
Patient dissatisfaction
Only 8% of patients are satisfied with medical therapy; 34% not satisfied at all
Large economic burden
>$10 billion in direct healthcare costs annually in the U.S.; indirect costs even higher
Decades of research and clinical experience support the gut microbiome as a relevant therapeutic target in IBS. While microbiome-modulating approaches, including diet, prebiotics, probiotics, antibiotics, and faecal microbiota transplantation (FMT), have shown benefit in subsets of patients, clinical effects have been variable and inconsistent.
EBX-102-02® builds on this evidence base, with the aim of becoming a first-in-class, orally delivered microbiome therapeutic for patients with IBS. EBX-102-02® has been evaluated in a Phase 2a clinical study in IBS as part of its ongoing development. EnteroBiotix intends to evaluate EBX-102-02® in a UK Ph2b study in 2026.
The potential of the gut microbiome in IBS
Development potential
Integrates clinical, safety and usability considerations within a microbiome-based therapeutic programme
Scientific rationale
Designed to restore the gut microbiome to achieve a locally acting, well-tolerated gastrointestinal effect
Clinical evidence to date
Phase 2a efficacy results in IBS-C presented as a late-breaking abstract at DDW 2025
Next clinical study
Phase 2b clinical study planned, with data anticipated following completion of enrolment and dosing
Partnering opportunity
We are seeking licensing partners to advance late-stage clinical development and commercialisation of EBX-102-02®
Our proprietary full-spectrum platform enables our differentiated approach
Number2® donor programme
Robust donor screening and management via Number2.org® platform ensures traceability, safety, and supply continuity
MHRA-licensed GMP manufacturing facilities
Licensed production platform enabling consistent, clinical-grade drug manufacturing at scale
Proprietary formulation technology
AMPLA™ drying converts raw material into a stable, odourless, orally dosed powder
Analytical & bioinformatics toolkit
Sophisticated capabilities
enable product quality
Development pipeline
Our clinical pipeline spans IBS, liver cirrhosis and adjuvant treatment in blood cancer
Meet our pioneering team
EBX is led by an experienced team, supported by a world-class Scientific Advisory Board
Join us in our mission
to orchestrate gut health
If you are passionate about improving the health of others and transforming lives, we are always looking for talented, ambitious, collaborative, and adaptable people
